Tempest發布了2024年第三季度財務業績報告及

提供業務更新

布里斯班，加州，2024年11月12日 – Tempest Therapeutics, Inc.（納斯達克：TPST），一家臨床階段的生物技術公司，正在開發首創的靶向和免疫介導的治療藥物來對抗癌症i ，今天發布了2024年9月30日結束的季度財務報告，並提供了企業最新動向。

“在第三季度，團隊持續成功地將艾美匝帕推向關鍵研究，並在監管和業務方面實現了重要里程碑，”Tempest的總裁兼首席執行官Stephen Brady表示。 “基於積極的隨機分期2數據和我們認為旨在成功的3期計劃，我們獲得了與FDA的廣泛協議。再加上Roche對3期研究的支持，第三季進一步鞏固了我們希望能為一線HCC患者帶來新的有意義療法的基礎。”

近期亮點

其他潛在未來里程碑

財務結果

2024年第三季度

本年至今

關於Tempest Therapeutics

Tempest Therapeutics是一家臨床階段的生物技術公司，推進一系列包含腫瘤靶向和/或免疫介導機制的小分子產品候選藥物組合，潛力可用於治療多種腫瘤。公司的新項目從早期研究到在第一線癌症患者中進行隨機全球研究的後期調查。 Tempest的總部位於加利福尼亞州布里斯班。有關Tempest的更多信息可在公司網站找到。 www.tempesttx.com.

前瞻性陳述

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials; Roche’s future supply of atezolizumab for use in the Company’s pivotal Phase 3 trial; anticipated therapeutic benefit and regulatory development of the Company’s product candidates; the Company’s anticipated cash runway; the Company’s ability to deliver on potential value-creating milestones; the Company’s ability to advance into a late-stage clinical company; and the Company’s ability to achieve its operational plans. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Any factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other documents filed by the Company from time to time with the Securities and Exchange Commission. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or

在其他情況下，這些前瞻性陳述不應作為Tempest Therapeutics在本新聞稿日期之後的任何日期代表意見的依據，也不應作為對未來事件的預測。鑒於前述情況，我們敦促投資者不要依賴任何前瞻性陳述來做出任何關於Tempest Therapeutics任何證券的結論或投資決定。

 

投資者聯絡方式：

Sylvia Wheeler

Wheelhouse生命科學顧問

swheeler@wheelhouselsa.com

艾爾賈那雷·雷諾茲

Wheelhouse生命科學顧問

areynolds@wheelhouselsa.com